The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells.
Momeny, Majid
The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells. [electronic resource] - Cellular oncology (Dordrecht, Netherlands) Aug 2019 - 491-504 p. digital
Publication Type: Journal Article
2211-3436
10.1007/s13402-019-00448-w doi
Apoptosis--drug effects
Carcinoma, Pancreatic Ductal--drug therapy
Cell Line, Tumor
Cell Movement--drug effects
Cell Proliferation--drug effects
Cell Survival--drug effects
ErbB Receptors--antagonists & inhibitors
Humans
Models, Biological
Neoplasm Invasiveness
Pancreatic Neoplasms--drug therapy
Quinazolinones--pharmacology
Radiation Tolerance
The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells. [electronic resource] - Cellular oncology (Dordrecht, Netherlands) Aug 2019 - 491-504 p. digital
Publication Type: Journal Article
2211-3436
10.1007/s13402-019-00448-w doi
Apoptosis--drug effects
Carcinoma, Pancreatic Ductal--drug therapy
Cell Line, Tumor
Cell Movement--drug effects
Cell Proliferation--drug effects
Cell Survival--drug effects
ErbB Receptors--antagonists & inhibitors
Humans
Models, Biological
Neoplasm Invasiveness
Pancreatic Neoplasms--drug therapy
Quinazolinones--pharmacology
Radiation Tolerance